New combo therapy shows promise in preventing breast cancer return
NCT ID NCT02654119
First seen Jan 07, 2026 · Last updated May 01, 2026 · Updated 18 times
Summary
This study tested a combination of two chemotherapy drugs (cyclophosphamide and paclitaxel) plus the targeted therapy trastuzumab given after surgery to 20 patients with early-stage HER2-positive breast cancer. The goal was to see if this regimen is safe and effective at preventing the cancer from coming back. The treatment aims to kill any remaining cancer cells and block their growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIA BREAST CANCER AJCC V6 AND V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Faith Regional Health Services Carson Cancer Center
Norfolk, Nebraska, 68701, United States
-
Nebraska Medicine-Village Pointe
Omaha, Nebraska, 68118, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.